Bulletin on Drug Safety - Current Issue 3/2025 Published
The Bulletin on Drug Safety is a cooperation between the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) and the Paul-Ehrlich-Institut (PEI). The quarterly publication provides information from both federal institutes on current aspects of the assessment of drugs. It focuses on pharmacovigilance – the continuous monitoring and evaluation of drug safety before and after marketing authorisation. The Bulletin includes articles on individual drugs as well as background information for understanding pharmacovigilance and research in this area.
The publication is available in German only.
Topics in the Current Issue
- Editorial: Ten years of the MedSafetyWeek international social media campaign
- Prescription of testosterone-containing medicinal products in Germany
- "We can all help make medicines safer" – the tenth anniversary of the international #MedSafetyWeek campaign
- Long-term consequences of COVID-19 disease and vaccination: prevCOV and COVYOUTHdata, BMG-funded research projects focused on Post-COVID and Post-Vac Syndrome
- Reports from BfArM and PEI
- PRAC recommendations within EU referral procedures – July to September 2025
- Revised product information wording – Extracts from the PRAC recommendations on signals
- References to direct healthcare professional communications (Rote-Hand-Briefe) and safety information
Further Information
Bulletin on Drug Safety, Issue 3/2025 (German only)
www.pei.de/bulletin-safety
